Biotech | August 10, 2021
Bayer strengthens drug discovery platform through acquisition of Vividion Therapeutics
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
Company working on COVID vaccine INO 4800
A veteran in cell therapy and oncology commercialisation
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
NPPA has capped the trade margin for Oxygen Concentrators at 70% on Price to Distributor (PTD) level
The group now has 320 approvals and has so far filed over 400 ANDAs
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
Pemetrexed is used to treat certain types of cancers such as lung cancer, mesothelioma. It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)
Subscribe To Our Newsletter & Stay Updated
